Partnering

Arena Pharmaceuticals, a San Diego-based biopharmaceutical company, and Outpost Medicine, a Lexington, Massachusetts-headquartered biopharmaceutical company focused on treatments for urologic and gynecologic diseases and disorders, have formed a licensing agreement…

Biogen has exercised its option in an agreement with Neurimmune, a Zurich, Switzerland-based biopharmaceutical company, to further reduce previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s…

Sandoz, Novartis’ generics arm, has partnered with Pear Therapeutics, a Boston, Massachusetts-based prescription digital therapeutics company, to commercialize Pear Therapeutics’ two lead products, reSET and reSET-O, digital therapeutics for treating…

Sanofi has purchased a platform from Berkeley Lights, an Emeryville, California-headquartered company developing platforms for biopharmaceutical processes, to accelerate its cell-line development process. Based on data from a pilot study,…

Biogen and Ionis Pharmaceuticals, a Carlsbad, California-based pharmaceutical company, have expanded their collaboration through a new 10-year collaboration agreement to develop antisense drug candidates for a range of neurological diseases…

Genentech, a Roche company, has signed an option and license agreement with Kineta Chronic Pain, a subsidiary of Kineta, a biopharmaceutical company, to develop Kineta’s α9/α10 nicotinic acetylcholine receptor (nAChR)…

Boehringer Ingelheim (BI) and Eli Lilly and Company have partnered in an academic collaboration with the University of Oxford to investigate the effects of the companies’ diabetes drug, Jardiance (empagliflozin),…

Bristol-Myers Squibb (BMS) and Illumina, a San Diego, California-headquartered company developing and commercializing systems for analysis of genetic variation and function, have partnered to use Illumina’s sequencing technology to develop…

Celgene Corporation and bluebird bio, a Cambridge, Massachusetts-based clinical-stage gene-therapy company, have agreed to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell…

Daiichi Sankyo Company and DarwinHealth, a New York-headquartered technology-focused cancer medicine company, have formed a research agreement providing Daiichi Sankyo with exclusive access to DarwinHealth’s proprietary cancer target database in…